Fruquintinib+mFOLFOX6/FOLFIRI

Phase 2Small molecule

Fruquintinib+mFOLFOX6/FOLFIRI is one of 7 small molecule programs targeting First Line Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First Line TherapyRecruiting

First Line TherapyPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in First Line Therapy

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

6 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 3

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 5

HB0025

SShanghai Huaota Biopharmaceutical Co., Ltd.

Phase 2

1 6

Fruquintinib+mFOLFOX6/FOLFIRI

FFudan University

Phase 2

1 7

Induction Carboplatin

Radiation Therapy Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

First Line Therapy1 trial

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Recruiting·FFudan University·Phase 2·NCT06010888·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fruquintinib+mFOLFOX6/FOLFIRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fruquintinib+mFOLFOX6/FOLFIRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fruquintinib+mFOLFOX6/FOLFIRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

Fruquintinib+mFOLFOX6/FOLFIRI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

First Line Therapy1 trial

References

Drug Info

Quick Facts

Related News